GlassScriptPhysician profile
Virali Patel
NPI 1851702989
$3,676.20
in general payments reported to CMS, 2019-2025
34 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $31.43 · 2022: $327 · 2023: $880 · 2024: $699 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,141.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $551.62 | 2022-2025 | |
| Lilly USA, LLC | $444.38 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $240.68 | 2022-2025 | Breztri, Farxiga, Flumist Quadrivalent |
| Pfizer INC. | $229.25 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $168.12 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.88 | 2022-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.75 | 2025 | Caplyta |
| Exact Sciences Corporation | $122.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $93.38 | 2022 | |
| Astellas Pharma US INC | $84.13 | 2022-2025 | Veozah, Xtandi |
| Phathom Pharmaceuticals, INC. | $83.65 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $74.27 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $70.02 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $66.47 | 2025 | Fanapt |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $57.16 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $50.45 | 2019 | |
| Amgen INC. | $49.50 | 2023-2024 | Otezla, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.43 | 2019-2020 | |
| Tempus Ai, INC | $46.15 | 2024 | |
| Glaxosmithkline, LLC. | $33.67 | 2023 | Shingrix, Arexvy |
| Halozyme INC | $33.56 | 2023 | |
| Sanofi-Aventis U.S. LLC | $30.09 | 2022 | |
| Edwards Lifesciences Corporation | $23.68 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $23.42 | 2019 | |
| Ironshore Pharmaceuticals INC. | $23.22 | 2023 | Jornay Pm |
| Dynavax Technologies Corporation | $22.50 | 2023 | Heplisav-B |
| Dexcom, INC. | $21.12 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $16.79 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.72 | 2022 | |
| Boston Scientific Corporation | $15.67 | 2019 | |
| Antares Pharma, INC. | $15.40 | 2024 | Xyosted |
| Sanofi Pasteur INC. | $12.89 | 2023 | |
| Allergan, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virali Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.